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Abstract: Paraneoplastic pemphigus is a rare autoimmune skin disease that is always associated
with a neoplasm. Usually, oral, skin, and mucosal lesions are the earliest manifestations shown
by paraneoplastic pemphigus patients. The pathogenesis of paraneoplastic pemphigus is not
yet completely understood, although some immunological aspects have been recently clarified.
Because of its rarity, several diagnostic criteria have been proposed. Besides, several diagnostic
procedures have been used for the diagnosis, including indirect immunofluorescence, direct
immunofluorescence, and ELISA. We reviewed the most recent literature, searching on PubMed
“paraneoplastic pemphigus”. We included also papers in French, German, and Spanish. We found
613 papers for “paraneoplastic pemphigus”. Among them, 169 were review papers. Because of
its varying clinical features, paraneoplastic pemphigus still represents a challenge for clinicians.
Furthermore, diagnosis and management of paraneoplastic pemphigus requires close collaboration
between physicians, including dermatologist, oncologist, and otorhinolaryngologist.
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1. Introduction
Paraneoplastic pemphigus (PNP) was first reported by Anhalt in 1990 [1]. It is a rare autoimmune
skin disease belonging to the group of blistering diseases. PNP is always characterized by an association
with neoplasms, including carcinoma of the stomach, lung, and colon [2]. Besides, B-cell lymphomas
and hematological malignancies are most frequently reported in association with PNP [3,4]. In 2001
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Nguyen et al. introduced the concept of paraneoplastic autoimmune multiorgan syndrome (PAMS),
highlighting the systemic nature of PNP [5]. In this regard, it should be noted that these patients usually
show a multi-organs involvement and different subsets of auto-antibodies to several tissues [1,3,6].
PNP shows a mortality rate up to 90%, and its early diagnosis is not simple [6,7]. Therefore, every
effort must be made to diagnose PNP as earliest as possible [1,2,5].
2. Epidemiology
Specific data regarding the incidence of PNP are still not available, but it is considered as a rare
disease. Indeed, around 500 cases of PNP have been reported in the literature [8,9]. PNP accounts for
3–5% of all pemphigus cases [8–10]. It arises usually in patients aged between 45 and 70 years, without
any significant difference between male and female [3]. Furthermore, PNP can affect also children and
adolescents [11–14]. In this sub-group of patients, PNP is more frequently associated with Castleman’s
disease and hematologic malignant disorders [11,13].
3. Etiology
Up to 84% of all PNP cases are caused by hematologic neoplasms or disorders [3,9].
Lymphoproliferative disorders are the most frequent diseases associated with PNP [9]. Non-Hodgkin’s
lymphoma is the most common associated neoplasm (38.6%), followed by chronic lymphocytic
leukemia (18.4%), Castleman’s disease (18.4%), thymoma (5.5%), Waldenstrom’s macroglobulinemia
(1.2%), Hodgkin’s lymphoma (0.6%), and monoclonal gammopathy (0.6%) [3,9,15,16]. In addition,
carcinomas from epithelial cells (8.6%) [17–19] and sarcomas from mesenchymal lines (6.2%) [12,20–22]
have been described in association to PNP. Gastric cancers have been rarely reported as a PNP
trigger. Indeed, only three cases of PNP related to gastric cancers (1 gastric lymphoma and two
adenocarcinomas) have been reported in the literature [23,24]. A single PNP case caused by
melanoma, described as localized paraneoplastic pemphigus, has been reported [25]. However, Anhalt
criticized this report, because of lacking anti-desmoglein antibodies and clinical features of PNP [26].
Some PNP cases triggered by certain drugs, including fludarabin and bendamustine, have also been
described [26–28]. However, according to Anhalt [26], the number of drug-linked-PNP could be
underrated, because of the absence of a registry for comprehensive data acquisition regarding PNP.
Finally, a single PNP case associated with radiotherapy has been described [29].
4. Genetic
Recently, it has been reported that PNP was associated with the DRB1*03 allele and HLA-Cw*14
alleles. These genetic characteristics are more frequent in some PNP populations, such as Caucasian
and Chinese ones [30,31]. These conclusions were drawn respectively from a series of 13 Caucasian
French patients by Martel et al. [30] and of 19 Han Chinese patients by Liu et al. [31].
5. Pathogenesis
Although the pathogenesis of PNP is still not completely known, it is plausible that both
autoantibodies and cell-mediated immunity play a key role [1,3–5]. The most common auto-antibodies
detected in PNP were directed against the plakin family, including antibodies against the 210-kDa
envoplakin, the 190-kDa periplakin, the 250- and 210-kDa desmoplakins I and II, the 500-kDa plectin,
and the 230-kDa bullous pemphigoid (BP) antigen [32–35].
Antibodies directed against plakophilin 3 and desmocollins 1–3 have also been reported in
different papers [36,37]. Furthermore, it has been thought that autoantibodies against desmoglein-1
(DSG-1) and desmoglein-3 (DSG-3) might also play a pathogenic role in PNP [38,39], although
Amagai et al. found a 100% positivity only for anti-DSG-3 autoantibodies [38]. The protease
inhibitor A2-macroglobulin-like-1 (A2ML1) has been also thought to be a pathogenic element
in PNP [40,41]. Besides, recently, Tsuchisaka et al. reported that epiplakin was a PNP
autoantigen [42]. In that paper, epiplakin was detected in 72.9% of 48 PNP sera of Japanese patients by
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immunoprecipitation-immunoblotting [42]. In addition, the authors showed that epiplakin-negative
PNP cases did not develop bronchiolitis obliterans. Indeed, epiplakinis is reported as a target antigen
in PNP-related bronchiolitis obliterans [42].
PNP antibodies belong principally to the IgG class. However, IgA class has also been reported in
few cases [43–46]. More specifically, Mentink et al. detected by ELISA IgA autoantibodies only against
DSG-3 in a series of four PNP patients [47]. Interestingly, in only one patient the serum showed IgA,
but not IgG autoantibodies [43].
Cell-mediated immunity could also play a role in PNP [3,48]. Reich et al. found selective epidermal
activated CD8+ T-cells in PNP [49]. In addition, Cummins et al. reported some PNP patients without
any detectable autoantibodies [50]. Furthermore, Wade et al. detected MHC-restricted CD8+ cytotoxic
T cells, non-MHC-restricted CD56+, and CD68+ natural killer cells within the dermo-epidermal
junction of PNP lesions [51].
6. Clinical Features
PNP clinical features are extremely polymorphous and PNP lesions can be detected not only on
the skin, but also in different mucosae [1–3,11]. The presence of different autoantibodies could justify
the different clinical features in PNP patients [3].
Usually, a neoplasm is detected before the onset of PNP [1,8,52]. However, PNP is the first clinical
manifestation that leads to the detection of an occult tumor in about 30% of cases [3,9].
Usually, oral and skin lesions are the earliest manifestations [52–54].
Because the refractoriness of the oral mucosal and skin lesions to standard immunosuppression
therapy, patient should be screened for an underlying occult neoplasm [1,8]. Because of the lack of
standardization of a screening protocol for occult neoplasms, a pan-CT scan and flow cytometry on
peripheral blood should be mandatory; indeed, PNP is mostly associated to lymphoproliferative or
haematological neoplasms [1,8].
6.1. Oral Lesions
Oral mucosa is almost always involved [2,21]. Clinically, PNP often presents with oral erosions,
which are rarely preceded by vesicles or bulla. The lesions usually involve the vermillion border of the
lips (Figures 1 and 2). Ulceration may involve the entire oral mucosal surfaces and may represent the
sole manifestation of this condition. A painful stomatitis is also commonly shown caused by massive
erosion in the oropharynx [2,21,53,55].
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and proximal extremities [7,63]. PNP onset is highly variable. Patients may present with diffuse
erythema, vesiculo-bullous lesions, papules, scaly plaques, exfoliative erythroderma, erosions or
ulcerations. The erythema can be macular, urticarial, targetoid or polymorphous. Patients may initially
show erythema, and then develop bullae and erosions [5,10,15,16].
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A si gle patient may present different types of lesions, each of which is able to evolve from one
type to another [8,52]. Usually, cutaneous lesions resemble those seen in PV, BP, EM, or graft versus
host disease (GVHD) [16]. Furthermore, pustular and psoriasiform lesions have also been reported in
the literature [5].
The different clinical features could be due to the predominance of the cell-mediated or
humoral-mediated athoge ic mechanism [51]. On the one ha d, umoral-mediated cytotoxicity
usually causes a prominent PV-like appearance [3,5,52]; on the other ha d, cell-mediated cytotoxicity
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often determines lichenoid lesions [48,50]. Lichenoid lesions are frequently identified in children,
predominantly on the torso and limbs [12,13]. Furthermore, a unique case of pemphigus vegetans-like
PNP has been described [64,65].
Pediatric patients often show lichenoid PNP lesions rather than bullous skin lesions [57,66]. In a
series of 14 PNP pediatric patients, it has been reported that all of them demonstrated antibodies to
plakins [12].
6.4. Pulmonary Manifestations
PNP affects also the respiratory epithelium in up to 92.8% of cases [11,51], leading to dyspnea,
obstructive lung disease, and bronchiolitis obliterans, which is one of the principal causes of death
in PNP patients [9,67]. Pulmonary involvement is commoner in children and Chinese patients with
Castelman’s disease [67]. Recently, Tsuchisaka et al. reported a correlation between epiplakin and
bronchiolitis obliterans in Japanese PNP patients [42]. Furthermore, the authors reported that 71% of
patients were affected by bronchiolitis obliterans pneumonia that led to a worse prognosis despite
treatment of the underlying malignancy [12,42,57].
7. Pathology
Pathological findings are related to the clinical features, showing different pathological
characteristics according to the examined lesion [7,39]. When blisters are present, suprabasal
acantholysis with sparse inflammatory infiltrates is usually evident on skin biopsy (Figure 5) [39],
while interface and lichenoid dermatitis are usually detected if inflammatory maculopapular lesions
are present [39,50]. In addition, lesions with mixed clinical features might show both acantholysis and
lichenoid interface dermatitis [8,53,54]. Dyskeratosis with suprabasal acantholysis is an important
finding that leads to the diagnosis of PNP [8]. (Figure 6) However, sometimes the acantholysis is
difficult to find, leading to important diagnostic pitfalls with other diseases as erythema multiforme,
Stevens–Johnson syndrome, GVHD, and drug reactions. Finally, it is important to highlight that
pathological findings could be compatible with a diagnosis of PNP even when the results of direct
immunofluorescence (DIF) are negative [8,53]. Indeed, DIF findings are important because the cells
involved in PNP include autoantibodies and CD8+ T cells that attack proteins in different layers of the
keratin, leading to different DIF features, including intercellular cement substance staining and/or
dermo-epidermal junction staining [8,53] (Figure 7).
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substrates could be used to perform indirect immunofluorescence (IIF), including normal human
skin, monkey esophagus, rat bladder, rat myocardium, and rat lung [71]. IIF identifies autoantibodies
directed against plakins, among which autoantibodies to envoplakin and periplakin are the most
specific [39]. On the one hand, IIF on normal human skin has been reported as positive in up to 50%;
on the other hand, IIF on rat bladder urothelium has been found positive in 75% of cases, displaying a
better sensitivity [72]. In addition, IIF on rat bladder has a high specificity (83%) [1,72]. Therefore, IIF
on rat bladder is now thought as a useful screening test for PNP. However, autoantibodies directed
against plakins have been also shown in other dermatoses, including PV, pemphigus foliaceus, and
TEN [72–74].
Immunoprecipitation (IP) is considered the gold standard for diagnosing PNP [75]. IP can show
antibodies against several antigens, including plakins and α-2-macroglobulin-like-1 [40]. In addition,
a positive IP has been reported by Camisa et al. as a major criterion for diagnosing PNP [76].
Immunoblotting (IB) could be used to detect antibodies against desmoplakin 1 and 2, periplakin,
and envoplakin on normal human keratinocytes extract [39,71].
9. Diagnosis
According to Anahlt et al. [1] the diagnostic criteria include five different points (Table 1).
Subsequently, Camisa et al. [76] introduced different criteria, including major and minor ones.
According to Camisa et al., three major or two major and two minor criteria are needed to diagnose
PNP [76]. More recently, Mimouni et al. [12] revised the original criteria by Anahlt et al. In this new
classification DIF was considered as a non-essential criterion for diagnosing PNP, because of its low
sensibility [71,72]. IIF on rat bladder urothelium and monkey esophagus are considered useful in
screening for detecting PNP [71,72]. A scheme depicting the diagnostic algorithm is shown in Table 2.
Table 1. Diagnostic criteria [1,12,75].
Parameter Criterion
Clinical features
Painful erosions involving mucosae with or without a multiform skin
eruption producing blisters and erosions, occurring in association with
an occult or evident neoplasm
Histopathology Suprabasal intraepithelial acantholysis, vacuolar interface changes,necrosis of individual keratinocytes, and/or lichenoid inflammation
Direct immunofluorescence
Combined presence of IgG and complement (C3) granular-linear
deposition within the epidermal intercellular spaces and along the
basement-membrane zone
Indirect immunofluorescence Presence of circulating antibodies that target the intercellular zone ofstratified squamous or transitional epithelia
Immunoprecipitation
Typical complex of proteins, including desmoplakin I (250 kD), bullous
pemphigoid antigen (230 kD), envoplakin (210 kD), desmoplakin II (210
kD), periplakin (190 kD) and α-2-macroglobulin-like-1 (170 kD)
Table 2. Resume of PNP diagnostic algorithm.
CLINIC Bullous Lesions on Skin and Mucous Membranes
PATHOLOGY Acantholysis (intraepidermal bulla) Sub-epidermal cleavage
DIF
Combined presence of IgG and complement (C3)
granular-linear deposition within the epidermal intercellular
spaces and along the basement-membrane zone
IIF Presence of circulating antibodies that target the intercellularzone of stratified squamous or transitional epithelia
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LABORATORY
AAB directed to several proteins, including desmoplakin I
(250 kD), bullous pemphigoid antigen (230 kD), envoplakin
(210 kD), desmoplakin II (210 kD), periplakin (190 kD) and
α-2-macroglobulin-like-1 (170 kD)
IgG anti-DSG 1 and 3
IgG anti-DSG 1
IgA anti-DSC
DIAGNOSIS
PNP
PV
PF
IgAP
Exclusion of PNP
Abbreviations: PNP Paraneoplastic pemphigus; DIF Direct immunofluorescence; IIF Indirect immunofluorescence;
AAB Autoantibodies; PV Pemphigus vulgaris; PF Pemphigus foliaceus; IgAP IgA pemphigus.
10. Differential Diagnosis
Differential diagnosis includes PV, BP, and EM. A more complete list is shown in Table 3.
Other diseases with mucous skin involvement should always be excluded [77,78]. Clinically, PNP
and PV may share many features, but PNP shows blisters developing from inflammatory papules or
macules, while PV usually shows blisters on the erythematous background. In addition, PNP could
show antibodies anti-A2ML1, anti-envoplakin, and anti-periplakin, highly specific for PNP [71–74].
Furthermore, DIF shows epithelial cell-surface IgG depositions with concurrent basement membrane
zone IgG depositions, considered a hallmark feature of PNP [71,72]. Finally, unlike other autoimmune
blistering diseases, PNP antibodies stain rat bladder epithelium. BP also shares some features with
PNP, especially when BP230 and BP180 are detected in PNP. However, DIF in PNP could show the
presence of epidermal intercellular deposits of IgG and complement C3, which are not found in BP.
EM-like lesions resembling TEN could also be present in PNP, but the detection of auto-antibodies
leads to PNP diagnosis [1–3,71–74].
Table 3. Differential diagnosis.
Differential Diagnosis
Pemphigus vulgaris
Bullous pemphigoid
Major aphthous stomatitis
Oral lichen planus
Lichen planus
Drug eruption
Erythema multiforme
GVHD
Stevens–Johnson syndrome
Toxic epidermal necrolysis
It is important to highlight that oral and cutaneous PNP lesions can be variable and resemble
many other diseases, both clinically and histologically. Therefore, an otolaryngologic examination
is essential for the evaluation of the lesions and of the differential diagnosis with other oral cavity
pathologies [2,21,53,55].
In patients with oral lesions, histologic findings, cutaneous lesions, and IIF support the diagnosis
of PNP [21,53,55].
11. Treatment Options
PNP therapy remains challenging because of the rarity of the disease. Although several medical
therapies have been suggested in the literature, PNP has been considered as more resistant to medical
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therapies in comparison to other forms of pemphigus [16,79]. When PNP is suspected, it could be useful
to follow the six steps reported by Frew et al. for better management of the patient [80]. This series of
steps includes stabilization of vital parameters, evaluation of any underlying malignancy, accurate
diagnosis of PNP, removal and medical therapy of the trigger tumor, and treatment of PNP using
immunosuppression, immunomodulation, or plasmapheresis. The first step is of capital importance
because of the high rate of mortality. Therefore, the stabilization of the patient represents the first
measure in the management of PNP patients [80].
High-dose corticosteroids are still considered as first line therapy [81,82]. However, steroids
only improve the skin lesion, while mucosal involvement it is not usually affected by steroids [54,83].
Indeed, one of the most important clinical features of PNP is the resistance of the mucosal lesions to
most types of therapy [83]. Nevertheless, high-dose prednisolone is still recommended as the first line
of treatment [80].
It has been reported that the association between prednisolone and other drugs,
including azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, intravenous
immunoglobulin (IVIG), and plasmapheresis show a good profile of efficacy and safety in selected
patients [1,54,81,84–88]. However, mucosal lesions are usually also resistant to combination therapy
regimen [83].
Rituximab, an anti-CD20 monoclonal antibody, has been reported as effective in PNP patients
caused by B-cell lymphoma [89,90]. Several rituximab schedules have been reported in the literature,
including monotherapy (375 mg/m2 weekly for four weeks) followed by eight weekly infusions and
weekly infusions for four weeks under corticosteroids and other immunosuppressive drugs, such as
cyclosporine A [80].
It has been reported that alemtuzumab, a humanized monoclonal antibody that binds CD52,
induced long-term remission in a patient with B-cell chronic lymphocytic leukemia [91]. This treatment
was used in a patient refractory to many of previous treatment, including corticosteroids, cyclosporine,
and IVIG. Alemtuzumab was administered 30 mg intravenously three times a week for 12 weeks,
showing improvement of mucosal and cutaneous lesions. Twelve months later, the patient was still in
remission on maintenance therapy (500 mg mycophenolate mofetil and 5 mg prednisone) [80,91].
Daclizumab, a humanized monoclonal antibody against the alpha subunit of the IL-2 receptor of
T cells, is thought to be a promising therapy for PNP [54].
Early antimicrobial therapy is recommended, because of the risk of sepsis following loss of skin
integrity and iatrogenic immunosuppression [16]. Antalgic therapy could be useful in reducing the
pain caused by extensive erosions [16].
12. Prognosis
The prognosis of PNP is generally poor (90% mortality rate) [8,16]. Death is usually due to
systemic complications, including sepsis, gastrointestinal bleeding, and bronchiolitis obliterans [8,16].
It has been reported that PNP and underlying malignancy do not have a parallel evolution [3,8,16].
Indeed, PNP lesions generally progress after removing the triggering malignancy or even when the
malignancy is under control [11,13,16]. However, it has been shown that outcome is better in PNP
patients with concurrent Castleman’s disease or benign thymomas after removing the tumor [92].
Finally, the prognosis of PNP depends on an appropriate management, including the effective
control of the oral and skin lesions, an adequate treatment of the underlying neoplasm, and prevention
of bronchiolitis obliterans. Therefore, it is mandatory to monitor vigilantly the patient and to treat
aggressively the disease [8,16].
13. Conclusions
Because of its various clinical features, PNP represents a challenge for the clinician.
In order to detect PNP earlier and to treat patients better, a cooperation between dermatologists,
oncologists, otolaryngologists, ophthalmologists, and surgeons is recommended. Although different
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immunological markers have been found, the pathogenesis of PNP is still unknown. Management of
the underlying tumor is of paramount importance. However, several therapies have been attempted
to treat this potentially lethal condition.
Author Contributions: Giovanni Paolino, Dario Didona and Giannicola Iannella conceived and designed the
experiments; Giuseppe Magliulo, Giannicola Iannella, Biagio Didona, Santo Raffaele Mercuri, Elisa Moliterni
and Michele Donati performed the bibliographic research; Giuseppe Magliulo, Biagio Didona, Andrea Ciofalo,
Guido Granata, Patricia Ranuzzi, Vincenzo Falasca and Stefano Calvieri analyzed the data; Giovanni Paolino,
Dario Didona and Giannicola Iannella wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Anhalt, G.J.; Kim, S.C.; Stanley, J.R.; Korman, N.J.; Jabs, D.A.; Kory, M.; Izumi, H.; Ratrie, H.; Mutasim, D., 3rd;
Ariss-Abdo, L. Paraneoplastic pemphigus. An autoimmune mucocu-taneous disease associated with
neoplasia. N. Engl. J. Med. 1990, 323, 1729–1735. [CrossRef] [PubMed]
2. Kelly, S.; Schifter, M.; Fulcher, D.A.; Lin, M.W. Paraneoplastic pemphigus: Two cases of intra-abdominal
malignancy presenting solely as treatment refractory oral ulceration. J. Dermatol. 2015, 42, 300–304.
[CrossRef] [PubMed]
3. Sehgal, V.N.; Srivastava, G. Paraneoplasticpemphigus/paraneoplastic autoimmune multiorgansyn-drome.
Int. J. Dermatol. 2009, 48, 162–169. [CrossRef] [PubMed]
4. Baum, S.; Sakka, N.; Artsi, O.; Trau, H.; Barzilai, A. Diagnosis and classification of autoimmune blistering
diseases. Autoimmun. Rev. 2014, 13, 482–489. [CrossRef] [PubMed]
5. Nguyen, V.T.; Ndoye, A.; Bassler, K.D.; Shultz, L.D.; Shields, M.C.; Ruben, B.S.; Webber, R.J.; Pittelkow, M.R.;
Lynch, P.J.; Grando, S.A. Classification, clinical manifestations, and im-munopathological mechanisms of the
epithelial variant of paraneoplastic autoimmune multi-organ syndrome: A reappraisal of paraneoplastic
pemphigus. Arch. Dermatol. 2001, 137, 193–206. [PubMed]
6. Sinha, A.A. Paraneoplastic pemphigus: Autoimmune-cancer nexus in the skin. Anticancer Agents Med. Chem.
2015, 15, 1215–1223. [CrossRef] [PubMed]
7. Anhalt, G.J. Paraneoplastic pemphigus. J. Investig. Dermatol. Symp. Proc. 2004, 9, 29–33. [CrossRef] [PubMed]
8. Vassileva, S.; Drenovska, K.; Manuelyan, K. Autoimmune blistering dermatoses as systemic diseases.
Clin. Dermatol. 2014, 32, 364–375. [CrossRef] [PubMed]
9. Czernik, A.; Camilleri, M.; Pittelkow, M.R.; Grando, S.A. Paraneoplastic autoimmune multiorgan syndrome:
20 years after. Int. J. Dermatol. 2011, 50, 905–914. [CrossRef] [PubMed]
10. Sticherling, M.; Erfurt-Berge, C. Autoimmune blistering diseases of the skin. Autoimmun. Rev. 2012, 11,
226–230. [CrossRef] [PubMed]
11. Cervini, A.B.; Tosi, V.; Kim, S.H.; Bocian, M.; Chantada, G.; Nousari, C.; Carballo, O.G.; Pierini, A.M.
Paraneoplastic pemphigus or paraneoplastic autoimmune multiorgan syndrome. Report of 2 cases in
children and a review of the literature. Actas Dermosifiliogr. 2010, 101, 879–886. [CrossRef] [PubMed]
12. Mimouni, D.; Anhalt, G.J.; Lazarova, Z.; Aho, S.; Kazerounian, S.; Kouba, D.J.; Mascaro, J.M., Jr.; Nousari, H.C.
Paraneoplastic pemphigus in children and adolescents. Br. J. Dermatol. 2002, 147, 725–732. [CrossRef]
[PubMed]
13. Lane, J.E.; Woody, C.; Davis, L.S.; Guill, M.F.; Jerath, R.S. Paraneoplastic autoimmune multiorgan syndrome
(para-neoplastic pemphigus) in a child: Case report and review of the literature. Pediatrics 2004, 114, 513–516.
[CrossRef] [PubMed]
14. Geller, S.; Gat, A.; Harel, A.; Mashiah, J.; Zeeli, T.; Eming, R.; Ishii, N.; Hertl, M.; Hashimoto, T.; Sprecher, E.
Childhood pemphigus foliaceus with exclusive immunoglobulin G autoantibodies to desmocollins.
Pediatr. Dermatol. 2016, 33, 10–13. [CrossRef] [PubMed]
15. Ohzono, A.; Sogame, R.; Li, X.; Teye, K.; Teye, K.; Tsuchisaka, A.; Numata, S.; Koga, H.; Kawakami, T.;
Tsuruta, D.; et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus.
Br. J. Dermatol. 2015, 173, 1447–1452. [CrossRef] [PubMed]
16. Yong, A.A.; Tey, H.L. Paraneoplastic pemphigus. Australas. J. Dermatol. 2013, 54, 241–250. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2017, 18, 2532 12 of 15
17. Bowen, G.M.; Peters, N.T.; Fivenson, D.P.; Su, L.D.; Nousari, H.C.; Anhalt, G.J.; Cooper, K.D.;
Stevens, S.R. Lichenoid dermatitis in paraneoplastic pemphigus: A pathogenic trigger of epitope spreading?
Arch. Dermatol. 2000, 136, 652–656. [CrossRef] [PubMed]
18. Matz, H.; Milner, Y.; Frusic-Zlotkin, M.; Brenner, S. Paraneoplastic pemphigus associated with pancreatic
carcinoma. Acta Derm-Venereol. 1997, 77, 289–291. [PubMed]
19. Wong, K.C.; Ho, K.K. Pemphigus with pemphigoid-like presentation, associated with squa-mous cell
carcinoma of the tongue. Australas. J. Dermatol. 2000, 41, 178–180. [CrossRef] [PubMed]
20. Lee, I.J.; Kim, S.C.; Kim, H.S.; Bang, D.; Yang, W.I.; Jung, W.H.; Chi, H.S. Paraneoplastic pemphigus associated
with follicular dendritic cell sarcoma arising from Castleman’s tumor. J. Am. Acad. Dermatol. 1999, 40,
294–297. [CrossRef]
21. Van der Wall, R.I.; Pas, H.H.; Anhalt, G.J.; Schulten, E.A.; Jonkman, M.F.; Nieboer, C. PNP as the presenting
symptom of lymphoma of the tongue. Oral Oncol. 1998, 34, 567–570. [CrossRef]
22. Su, Z.; Liu, G.; Liu, J.; Fang, T.; Zeng, Y.; Zhang, H.; Yang, S.; Wang, Y.; Zhang, J.; Wei, J.; et al. Paraneoplastic
pemphigus associated with follicular dendritic cell sarcoma: Report of a case and review of literature. Int. J.
Clin. Exp. Pathol. 2015, 8, 11983–11994. [PubMed]
23. Basir, N.; Telisinghe, P.U.; Chong, V.H. Gastric cancer and paraneoplastic pemphigus. Indian J. Surg. 2015, 77,
545–546. [CrossRef] [PubMed]
24. Ahmed, A.R.; Avram, M.M.; Duncan, L.M. Case records of the Massachusetts General Hospital. Weekly
clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive
mucosal and cutaneous lesions. N. Engl. J. Med. 2003, 349, 382–391. [CrossRef] [PubMed]
25. Schaeppi, H.; Bauer, J.W.; Hametner, R.; Metze, D.; Ortiz-Urda, S.; Salmhofer, W.; Rappersberger, K.;
Hintner, H. Localized variant of paraneoplastic pemphigus: Acantho-lysis associated with malignant
melanoma. Br. J. Dermatol. 2001, 144, 1249–1254. [CrossRef] [PubMed]
26. Anhalt, G.J. Paraneoplastic pemphigus: The role of tumours and drugs. Br. J. Dermatol. 2001, 144, 1102–1104.
[CrossRef] [PubMed]
27. Bazarbachi, A.; Bachelez, H.; Dehen, L.; Delmer, A.; Zittoun, R.; Dubertret, L. Lethal paraneoplastic
pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine. Ann. Oncol. 1995, 6,
730–731. [CrossRef] [PubMed]
28. Higo, T.; Miyagaki, T.; Nakamura, F.; Shinohara, A.; Asano, H.; Abe, H.; Senda, N.; Yoshizaki, A.;
Fukayama, M.; Kurokawa, M. Paraneoplastic pemphigus occurring after bendamustine and rituximab
therapy for relapsed follicular lymphoma. Ann. Hematol. 2015, 94, 683–685. [CrossRef] [PubMed]
29. Lee, M.S.; Kossard, S.; Ho, K.K.; Barnetson, R.S.; Ravich, R.B. Paraneoplastic pemphigus triggered by
radiotherapy. Australas. J. Dermatol. 1995, 36, 206–210. [CrossRef] [PubMed]
30. Martel, P.; Loiseau, P.; Joly, P.; Busson, M.; Lepage, V.; Mouquet, H.; Courville, P.; Flageul, B.; Charron, D.;
Musette, P.; et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J. Autoimmun. 2003, 20,
91–95. [CrossRef]
31. Liu, Q.; Bu, D.F.; Li, D.; Zhu, X.J. Genotyping of HLA-I and HLA-II alleles in Chinese patients with
para-neoplastic pemphigus. Br. J. Dermatol. 2008, 158, 587–591. [CrossRef] [PubMed]
32. Kiyokawa, C.; Ruhrberg, C.; Nie, Z.; Karashima, T.; Mori, O.; Nishikawa, T.; Green, K.J.; Anhalt, G.J.; Di
Colandrea, T.; Watt, F.M.; et al. Envoplakin and periplakin are components of the paraneoplastic pemphigus
antigen complex. J. Investig. Dermatol. 1998, 111, 1236–1238. [CrossRef] [PubMed]
33. Kim, S.C.; Kwon, Y.D.; Lee, I.J.; Chang, S.N.; Lee, T.G. cDNA cloning of the 210-kDa paraneoplastic
pemphigus antigen reveals that envoplakin is a component of the antigen complex. J. Investig. Dermatol.
1997, 109, 365–369. [CrossRef] [PubMed]
34. Oursler, J.R.; Labib, R.S.; Ariss-Abdo, L.; Burke, T.; O’Keefe, E.J.; Anhalt, G.J. Human autoantibodies against
desmoplakins in paraneoplastic pemphigus. J. Clin. Investig. 1992, 89, 1775–1782. [CrossRef] [PubMed]
35. Borradori, L.; Trueb, R.M.; Jaunin, F.; Limat, A.; Favre, B.; Saurat, J.H. Autoantibodies from a patient with
paraneoplastic pemphi-gus bind periplakin, a novel member of the plakin family. J. Investig. Dermatol. 1998,
111, 338–340. [CrossRef] [PubMed]
36. Lambert, J.; Bracke, S.; van Roy, F.; Pas, H.H.; Bonné, S.; De Schepper, S. Serum plakophilin-3 autoreactivity
in paraneoplastic pemphigus. Br. J. Dermatol. 2010, 163, 630–632. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2532 13 of 15
37. Brandt, O.; Rafei, D.; Podstawa, E.; Niedermeier, A.; Jonkman, M.F.; Terra, J.B.; Hein, R.; Hertl, M.; Pas, H.H.;
Müller, R. Differential IgG recognition of desmoglein 3 by parane-oplastic pemphigus and pemphigus
vulgaris sera. J. Investig. Dermatol. 2012, 132, 1738–1741. [CrossRef] [PubMed]
38. Amagai, M.; Nishikawa, T.; Nousari, H.C.; Anhalt, G.J.; Hashimoto, T. Antibodies against desmoglein 3
(pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause
acantholysis in vivo in neonatal mice. Clin. Investig. 1998, 102, 775–782. [CrossRef] [PubMed]
39. Zimmermann, J.; Bahmer, F.; Rose, C.; Zillikens, D.; Schmidt, E. Clinical and immunopathological spectrum
of para-neoplastic pemphigus. J. Dtsch. Dermatol. Ges. 2010, 8, 598–606. [PubMed]
40. Numata, S.; Teye, K.; Tsuruta, D.; Sogame, R.; Ishii, N.; Koga, H.; Natsuaki, Y.; Tsuchisaka, A.; Hamada, T.;
Karashima, T.; et al. Anti-alpha-2-macroglobulinlike-1 autoantibodies are detected frequently and may be
pathogenic in paraneoplastic pemphigus. J. Investig. Dermatol. 2013, 133, 1785–1793. [CrossRef] [PubMed]
41. Schepens, I.; Jaunin, F.; Begre, N.; Läderach, U.; Marcus, K.; Hashimoto, T.; Favre, B.; Borradori, L. The
protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus
autoantibodies in human. PLoS ONE 2010, 18, e12250.
42. Tsuchisaka, A. Epiplakin Is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans
in Japanese Patients. J. Investig. Dermatol. 2016, 136, 399–408. [CrossRef] [PubMed]
43. Taintor, A.R.; Leiferman, K.M.; Hashimoto, T.; Ishii, N.; Zone, J.J.; Hull, C.M. A novel case of IgA
paraneoplastic pemphigus asso-ciated with chronic lymphocytic leukemia. J. Am. Acad. Dermatol. 2007, 56,
S73–S76. [CrossRef] [PubMed]
44. Yashiro, M.; Nakano, T.; Taniguchi, T.; Katsuoka, K.; Tadera, N.; Miyazaki, K.; Teye, K.; Koga, H.;
Hashimoto, T. IgA paraneoplastic pemphigus in angioimmunoblastic T-cell lymphoma with antibodies
to desmocollin 1, type vii collagen and laminin 332. Acta Derm. Venereol. 2013, 93, 235–236. [CrossRef]
[PubMed]
45. Fullerton, S.H.; Woodley, D.T.; Smoller, B.R.; Anhalt, G.J. Paraneoplastic pemphigus with autoantibody
deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA 1992, 267,
1500–1502. [CrossRef] [PubMed]
46. Preisz, K.; Horvath, A.; Sardy, M.; Somlai, B.; Hársing, J.; Amagai, M.; Hashimoto, T.; Nagata, Y.; Fekete, S.;
Kárpáti, S. Exacerbation of paraneoplastic pemphigus by cyclophosphamide treatment: Detection of novel
autoantigens and bronchial autoantibodies. Br. J. Dermatol. 2004, 150, 1018–1024. [CrossRef] [PubMed]
47. Mentink, L.F.; de Jong, M.C.; Kloosterhuis, G.J.; Zuiderveen, J.; Jonkman, M.F.; Pas, H.H. Coexistence of
IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic
pemphigus. Br. J. Dermatol. 2007, 156, 635–641. [CrossRef] [PubMed]
48. Billet, S.E.; Grando, S.A.; Pittelkow, M.R. Paraneoplastic autoimmune multiorgan syndrome: Re-view of
the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006, 39, 617–630. [CrossRef]
[PubMed]
49. Reich, K.; Brinck, U.; Letschert, M.; Blaschke, V.; Dames, K.; Braess, J.; Wörmann, B.; Rünger, T.M.;
Neumann, C. Graft-versus-host disease like immunophenotype and apoptotic keratinocyte death in
paraneoplastic pemphigus. Br. J. Dermatol. 1999, 141, 739–746. [CrossRef] [PubMed]
50. Cummins, D.L.; Mimouni, D.; Tzu, J.; Owens, N.; Anhalt, G.J.; Meyerle, J.H. Lichenoid paraneoplastic
pemphigus in the absence of detectable antibodies. J. Am. Acad. Dermatol. 2007, 56, 153–159. [CrossRef]
[PubMed]
51. Wade, M.S.; Black, M.M. Paraneoplastic pemphigus: A brief update. Australas. J. Dermatol. 2005, 46, 1–8.
[CrossRef] [PubMed]
52. Zhu, X.; Zhang, B. Paraneoplastic pemphigus. J. Dermatol. 2007, 34, 503–511. [CrossRef] [PubMed]
53. Bialy-Golan, A.; Brenner, S.; Anhalt, G.J. Paraneoplastic pemphigus: Oral involvement as the sole
manifestation. Acta Derm. Venereol. 1996, 76, 253–254. [PubMed]
54. Lee, S.E.; Kim, S.C. Paraneoplastic pemphigus. Dermatol. Sin. 2010, 28, 1–14. [CrossRef]
55. Healy, W.J.; Peters, S.; Nana-Sinkam, S.P. A middle-aged man presenting with unexplained mucosal erosions
and progressive dyspnoea. BMJ Case Rep. 2015. [CrossRef] [PubMed]
56. Mahajan, V.K.; Sharma, V.; Chauhan, P.S.; Mehta, K.S.; Sharma, A.L.; Abhinav, C.; Khatri, G.; Prabha, N.;
Sharma, S.; Negi, M. Paraneoplastic pemphigus: A paraneoplastic autoimmune multiorgan syndrome or
autoimmune multiorganopathy? Case Rep. Dermatol. Med. 2012, 2012, 207126. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2532 14 of 15
57. Mar, W.A.; Glaesser, R.; Struble, K.; Stephens-Groff, S.; Bangert, J.; Hansen, R.C. Paraneoplastic pemphigus
with bronchiolitis obliterans in a child. Pediatr. Dermatol. 2003, 20, 238–242. [CrossRef] [PubMed]
58. Chorzelski, T.; Hashimoto, T.; Maciejewska, B.; Amagai, M.; Anhalt, G.J.; Jablonska, S. Paraneoplastic
pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J. Am.
Acad. Dermatol. 1999, 41, 393–400. [CrossRef]
59. Meyers, S.J.; Varley, G.A.; Meisler, D.M.; Camisa, C.; Wander, A.H. Conjunctival involvement in
paraneoplastic pemphigus. Am. J. Ophthalmol. 1992, 114, 621–624. [CrossRef]
60. Ng, P.P.; Rencic, A.; Nousari, H.C. Paraneoplastic pemphigus: A refractory autoimmune mucocutaneous
disease. J. Cutan. Med. Surg. 2002, 6, 434–437. [CrossRef] [PubMed]
61. Yokokura, H.; Demitsu, T.; Kakurai, M.; Umemoto, N.; Azuma, R.; Yamada, T.; Suzuki, M.; Jimbu, Y.;
Yoneda, K.; Ishii, N.; et al. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated
with primary hepatocellular carcinoma. J. Dermatol. 2006, 33, 842–845. [CrossRef] [PubMed]
62. Broussard, K.C.; Leung, T.G.; Moradi, A.; Thorne, J.E.; Fine, J.D. Autoimmune bullous diseases with
skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica.
Clin. Dermatol. 2016, 34, 205–213. [CrossRef] [PubMed]
63. Mutasim, D.F.; Pelc, N.J.; Anhalt, G.J. Paraneoplastic pemphigus. Dermatol. Clin. 1993, 11, 473–481. [PubMed]
64. Tankel, M.; Tannenbaum, S.; Parekh, S. Paraneoplastic pemphigus presenting as an unusual bullous eruption.
J. Am. Acad. Dermatol. 1993, 29, 825–828. [CrossRef]
65. Sapadin, A.N.; Anhalt, G.J. Paraneoplastic pemphigus with a pemphigus vegetans-like plaque as the only
cutaneous manifestation. J. Am. Acad. Dermatol. 1998, 39, 867–871. [CrossRef]
66. Marathe, K.; Lu, J.; Morel, K.D. Bullous diseases: Kids are not just little people. Clin. Dermatol. 2015, 33,
644–656. [CrossRef] [PubMed]
67. Maldonado, F.; Pittelkow, M.R.; Ryu, J.H. Constrictive bronchiolitis associated with paraneoplastic
autoimmune multi-organ syndrome. Respirology 2009, 14, 129–133. [CrossRef] [PubMed]
68. Ishii, N.; Maeyama, Y.; Karashima, T.; Nakama, T.; Kusuhara, M.; Yasumoto, S.; Hashimoto, T.
Immunoserological analyses of 55 patients with pemphigus at the Dermatological Department of Kurume
University Hospital: An 11-year retrospective study (1996–2006). Int. J. Dermatol. 2008, 47, 1321–1322.
[CrossRef] [PubMed]
69. Probst, C.; Schlumberger, W.; Stöcker, W.; Recke, A.; Schmidt, E.; Hashimoto, T.; Zhu, X.J.; Zillikens, D.;
Komorowski, L. Development of ELISA for the specific determination of autoantibodies against envoplakin
and periplakin in paraneoplastic pemphigus. Clin. Chim. Acta 2009, 410, 13–18. [CrossRef] [PubMed]
70. Kelly, S.; Culican, S.; Silvestrini, R.A.; Vu, J.; Schifter, M.; Fulcher, D.A.; Lin, M.W. Comparative study of
five serological assays for the diagnosis of paraneoplastic pemphigus. Pathology 2015, 47, 58–61. [CrossRef]
[PubMed]
71. Joly, P.; Richard, C.; Gilbert, D.; Courville, P.; Chosidow, O.; Roujeau, J.C.; Beylot-Barry, M.; D’incan, M.;
Martel, P.; Lauret, P.; et al. Sensitivity and specificity of clinical, histologic, and immuno-logic features in the
diagnosis of paraneoplastic pemphigus. J. Am. Acad. Dermatol. 2000, 43, 619–626. [CrossRef] [PubMed]
72. Helou, J.; Allbritton, J.; Anhalt, G. Accuracy of indirect immunofluorescence in the diagnosis of
para-neoplastic pemphigus. J. Am. Acad. Dermatol. 1995, 32, 441–447. [CrossRef]
73. Cozzani, E.; Dal Bello, M.G.; Mastrogiacomo, A.; Drosera, M.; Parodi, A. Antidesmoplakin antibodies in
pemphigus vulgaris. Br. J. Dermatol. 2006, 154, 624–628. [CrossRef] [PubMed]
74. Kazerounian, S.; Mahoney, M.G.; Uitto, J.; Aho, S. Envoplakin and periplakin, the paraneoplastic pemphigus
antigens, are also recognized by pemphigus foliaceus autoantibodies. J. Investig. Dermatol. 2000, 115, 505–507.
[CrossRef] [PubMed]
75. Hashimoto, T.; Amagai, M.; Watanabe, K.; Chorzelski, T.P.; Bhogal, B.S.; Black, M.M.; Stevens, H.P.;
Boorsma, D.M.; Korman, N.J.; Gamou, S. Characterization of paraneoplastic pemphigus autoanti-gens
by immunoblot analysis. J. Investig. Dermatol. 1995, 104, 829–834. [CrossRef] [PubMed]
76. Camisa, C.; Helm, T.N. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch.
Dermatol. 1993, 129, 883–886. [CrossRef] [PubMed]
77. Iannella, G.; Greco, A.; Granata, G.; Manno, A.; Pasquariello, B.; Angeletti, D.; Didona, D.; Magliulo, G.
Granulomatosis with polyangiitis and facial palsy: Literature review and insight in the autoimmune
pathogenesis. Autoimmun. Rev. 2016, 15, 621–631. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2532 15 of 15
78. Iannella, G.; Greco, A.; Didona, D.; Didona, B.; Granata, G.; Manno, A.; Pasquariello, B.; Magliulo, G. Vitiligo:
Pathogenesis, clinical variants and treatment approaches. Autoimmun. Rev. 2016, 15, 335–343. [CrossRef]
[PubMed]
79. Lee, S.E.; Hashimoto, T.; Kim, S.C. No mucosal involvement in a patient with paraneoplastic pemphigus
associated with thymoma and myasthenia gravis. Br. J. Dermatol. 2008, 159, 986–988. [CrossRef] [PubMed]
80. Frew, J.W.; Murrell, D.F. Current management strategies in paraneoplastic pemphigus (paraneoplastic
autoimmune multiorgan syndrome). Dermatol. Clin. 2011, 29, 607–612. [CrossRef] [PubMed]
81. Gergely, L.; Váróczy, L.; Vadász, G.; Remenyik, E.; Illés, A. Successful treatment of B cell chronic lymphocytic
leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol. 2003, 109, 202–205.
[CrossRef] [PubMed]
82. Martínez De Pablo, M.I.; Iranzo, P.; Llambrich, A.; Baradad, M.; Herrero, C. Paraneoplastic pemphigus
associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm. Venereol. 2005,
85, 233–235. [PubMed]
83. Vezzoli, P.; Berti, E.; Marzano, A.V. Rationale and efficacy for the use of rituximab in paraneoplastic
pemphigus. Expert Rev. Clin. Immunol. 2008, 4, 351–364. [CrossRef] [PubMed]
84. Williams, J.V.; Marks, J.G.; Billingsley, E.M. Use of mycophenolate mofetil in the treatment of paraneoplastic
pemphigus. Br. J. Dermatol. 2000, 142, 506–508. [CrossRef] [PubMed]
85. Hertzberg, M.S.; Schifter, M.; Sullivan, J.; Stapleton, K. Paraneoplastic pemphigus in two patients with B-cell
non-Hodgkin’s lymphoma: Significant responses to cyclophosphamide and prednisolone. Am. J. Hematol.
2000, 63, 105–106. [CrossRef]
86. Tan-Lim, R.; Bystryn, J.C. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies.
J. Am. Acad. Dermatol. 1990, 22, 35–40. [CrossRef]
87. Izaki, S.; Yoshizawa, Y.; Kitamura, K.; Kato, H.; Hashimoto, H.; Korman, N.J.; Hamamatsu, Y.; Ohashi, N.;
Ogasa, S. Paraneoplastic pemphigus: Potential therapeutic effect of plasmapheresis. Br. J. Dermatol. 1996,
134, 987–989. [CrossRef] [PubMed]
88. Granata, G.; Greco, A.; Iannella, G.; Granata, M.; Manno, A.; Savastano, E.; Magliulo, G. Posterior
reversible encephalopathy syndrome—Insight into pathogenesis, clinical variants and treatment approaches.
Autoimmun. Rev. 2015, 14, 830–836. [CrossRef] [PubMed]
89. Hertl, M.; Zillikens, D.; Borradori, L.; Bruckner-Tuderman, L.; Burckhard, H.; Eming, R.; Engert, A.;
Goebeler, M.; Hofmann, S.; Hunzelmann, N.; et al. Recommendations for the use of rituximab (anti-CD20
antibody) in the treatment of autoimmune bullous skin diseases. J. Dtsch. Dermatol. Ges. 2008, 6, 366–373.
[CrossRef] [PubMed]
90. Hainsworth, J.D.; Burris, H.A.; Morrissey, L.H.; Litchy, S.; Scullin, D.C., Jr.; Bearden, J.D., 3rd; Richards, P.;
Greco, F.A. Rituximab monoclonal antibody as initial systemic therapy for patients with lowgrade
non-Hodgkins lymphoma. Blood 2000, 95, 3052–3056. [PubMed]
91. Hohwy, T.; Bang, K.; Steiniche, T.; Peterslund, N.A.; d’Amore, F. Alemtuzumab-induced remission of both
severe para-neoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant
B-cell chronic lymphocytic leukaemia. Eur. J. Haematol. 2004, 73, 206–209. [CrossRef] [PubMed]
92. Wang, J.; Zhu, X.; Li, R.; Tu, P.; Wang, R.; Zhang, L.; Li, T.; Chen, X.; Wang, A.; Yang, S.; et al. Paraneoplastic
pemphigus associated with Castleman tumor: A commonly reported subtype of paraneoplastic pemphigus
in China. Arch. Dermatol. 2005, 141, 1285–1293. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
